S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
NASDAQ:ORIC

ORIC Pharmaceuticals Insider Trades

$23.74
-0.66 (-2.70 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$23.41
$24.50
50-Day Range
$15.90
$25.22
52-Week Range
$15.67
$40.81
Volume93,600 shs
Average Volume235,046 shs
Market Capitalization$933.41 million
P/E RatioN/A
Dividend YieldN/A
Beta2.91

ORIC Pharmaceuticals (NASDAQ:ORIC) Insider Buying and Selling Activity

24.64% of ORIC Pharmaceuticals' shares are owned by company executives, directors and other insiders. Over the past twelve months, ORIC Pharmaceuticals insiders have sold shares 29 time(s), totalling $9,735,825.86. Insiders that have sold shares include Jacob Chacko, Richard A. Heyman, Richard A Heyman, Richard H Scheller, Carl L Gordon, and Orbimed Advisors Llc.

Insider Buying and Selling by Quarter


ORIC Pharmaceuticals (NASDAQ ORIC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/15/2021Jacob ChackoCEOSell3,736$25.06$93,624.166,388  
9/14/2021Richard A. HeymanDirectorSell706$25.05$17,685.3012,500  
9/13/2021Jacob ChackoCEOSell2,801$25.02$70,081.026,388  
9/10/2021Jacob ChackoCEOSell2,942$25.08$73,785.36  
9/7/2021Jacob ChackoCEOSell5,981$25.11$150,182.9116,751  
9/7/2021Richard A HeymanDirectorSell1,086$25.11$27,269.4612,500  
5/24/2021Jacob ChackoCEOSell12$25.00$300.0027,934  
5/24/2021Richard A HeymanDirectorSell100$25.00$2,500.0012,500  
5/20/2021Jacob ChackoCEOSell2,468$25.07$61,872.7627,934  
5/20/2021Richard A HeymanDirectorSell700$25.08$17,556.0012,500  
5/17/2021Richard A HeymanDirectorSell498$25.07$12,484.8612,500  
5/13/2021Jacob ChackoCEOSell730$25.04$18,279.2059,310  
5/13/2021Richard H SchellerDirectorSell100$25.00$2,500.0049,200  
5/11/2021Jacob ChackoCEOSell1,090$25.22$27,489.8059,310  
5/11/2021Richard A HeymanDirectorSell100$25.11$2,511.0049,200  
4/30/2021Jacob ChackoCEOSell1,300$25.14$32,682.0061,000  
4/30/2021Richard A HeymanDirectorSell100$25.26$2,526.0012,500  
4/28/2021Jacob ChackoCEOSell700$25.06$17,542.0061,000  
4/28/2021Richard A HeymanDirectorSell100$25.08$2,508.0012,500  
4/1/2021Jacob ChackoCEOSell800$25.09$20,072.0061,700  
4/1/2021Richard H SchellerDirectorSell200$25.00$5,000.0049,800  
3/29/2021Carl L GordonDirectorSell75,555$23.31$1,761,187.05  
3/26/2021Orbimed Advisors LlcDirectorSell27,816$23.88$664,246.08  
3/24/2021Orbimed Advisors LlcDirectorSell32,959$24.80$817,383.20  
3/22/2021Carl L GordonDirectorSell7,673$26.47$203,104.31  
3/19/2021Carl L GordonDirectorSell21,275$26.47$563,149.25  
3/17/2021Orbimed Advisors LlcDirectorSell18,790$28.43$534,199.70  
3/15/2021Orbimed Advisors LlcDirectorSell89,210$29.14$2,599,579.40  
3/11/2021Orbimed Advisors LlcDirectorSell58,551$33.04$1,934,525.04  
4/24/2020Orbimed Advisors LlcDirectorBuy281,250$25.68$7,222,500.00
(Data available from 1/1/2013 forward)
speech bubbles
speech bubbles











ORIC Pharmaceuticals (NASDAQ:ORIC) Insider Trade Frequently Asked Questions

Who is on ORIC Pharmaceuticals's Insider Roster?

The list of insiders at ORIC Pharmaceuticals includes Carl L Gordon, Jacob Chacko, Orbimed Advisors Llc, Richard A Heyman, and Richard H Scheller.Learn more on ORIC's insiders

What percentage of ORIC Pharmaceuticals stock is owned by insiders?

24.64% of ORIC Pharmaceuticals stock is owned by insiders. Learn more on ORIC's insider holdings

Which ORIC Pharmaceuticals insiders have been buying company stock?

The following insider purchased ORIC Pharmaceuticals stock in the last 24 months: Orbimed Advisors Llc ($7,222,500.00).

How much insider buying is happening at ORIC Pharmaceuticals?

Insiders have purchased a total of 281,250 ORIC Pharmaceuticals shares in the last 24 months for a total of $7,222,500.00 bought.

Which ORIC Pharmaceuticals insiders have been selling company stock?

The following insiders have sold ORIC Pharmaceuticals stock in the last 24 months: Carl L Gordon ($2,527,440.61), Jacob Chacko ($565,911.21), Orbimed Advisors Llc ($6,549,933.42), Richard A Heyman ($67,355.32), and Richard H Scheller ($7,500.00).

How much insider selling is happening at ORIC Pharmaceuticals?

Insiders have sold a total of 358,079 ORIC Pharmaceuticals shares in the last 24 months for a total of $9,735,825.86 sold.

This page was last updated on 9/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.